Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Awards
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
    • Women in Healthcare
    • - Luminaries
    • - Top 25 Diversity Leaders
    • - Leaders to Watch
    • - Luminaries
    • - Top 25 Women Leaders
    • - Women to Watch
  • Events
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Leadership Symposium
    • Health Care Hall of Fame Gala
    • Top 25 Women Leaders Gala
    • Best Places to Work Awards Gala
    • Top 25 Diversity Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Strategic Marketing
    • - Virtual Health
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Finance
September 01, 2016 01:00 AM

Should the cost of naloxone be determined by its public health impact?

Steven Ross Johnson
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    vaccine

    The rising cost of naloxone—a 40-year-old drug capable of reversing drug overdoses—is prompting questions about the wisdom of allowing market-forces to determine the price of a vital tool in the public health response to the nation's opioid crisis.

    Some say the federal government should purchase the drug and distribute it to state and local health agencies at a more affordable price.

    Earlier this week, Baltimore health commissioner Dr. Leana Wen told Modern Healthcare that the cost of naloxone has prevented her department, which is at the forefront of the campaign to widen use of naloxone, from blanketing the city as she had hoped.

    Baltimore currently pays around $40 for a single dose of naloxone, compared to $20 a dose it was paying in July 2015. An analysis conducted by Truven Health Analytics found the price for the injectable version of naloxone rose from $0.92 a dose to more than $15 a dose over the last decade.

    “The rising costs of naloxone and other opioid overdose antidotes are causing local health departments to conserve dosages and train fewer people on naloxone usage,” said Dr. LaMar Hasbrouck, executive director for the National Association for County and City Health Officials.

    Expanded use of naloxone has been recommended by the Centers for Diseases Control and Prevention, which earlier this year recommended providers prescribe the drug alongside opioid pain medications.

    Over the past decade, many states have passed laws aimed at expanding use of naloxone. Currently, 42 states and the District of Columbia have criminal liability protections in place for first responders and the general public who administer the drug. A total of 42 states also allow naloxone to be distributed to first responders through a standing order, like Baltimore.

    Drugmakers have priced naloxone based on the expectation that they will be added to formularies of health insurance companies and pharmacy benefit managers, according to Daniel Raymond, policy director at the Harm Reduction Coalition. Such firms can negotiate prices because of the volume at which they purchase.

    Towns and states on the other hand buy directly from the manufacturers, many of whom have less purchasing power than that of insurers and PBMs.

    “It's important to approach this as somewhat of a bifurcated market,” Raymond said.

    Some public health organizations are relying on donations to maintain their supplies.

    Erin Taylor, an associate policy researcher at RAND Corp., wonders if the federal government should get involved.

    The government uses a similar type of purchasing model when purchasing vaccines for children. The CDC gets a discounted rate from producers to distribute to state and local health departments who provide them at no charge for eligible patients at federally qualified health clinics.

    Hasbrouck said a similar model to buy naloxone would be a great model to consider,” but added his agency has yet to develop a policy calling for such a move.

    In recent years, states have received block grants to purchase naloxone. Just this week, HHS announced it was allocating $53 million in funding to 44 states, four tribes and the District of Columbia to improve access to treatment for opioid use disorders and reduce opioid related deaths. Part of the funding package includes up to $11 million to 12 states to support training on preventing opioid-related overdose deaths and to purchase naloxone for first responders.

    Meantime, public health officials are pressuring drug makers to reveal the reasons for the skyrocketing costs.

    For its part, drug firm Kaleo, maker of the naloxone auto-injection product Evzio, stated that its prices were “reflective of innovation, years of extensive research to ensure the device is easy to use and reliable and to ensure the broadest access to this potentially life-saving product,” according to the company Vice President Mark Herzog.

    But while the mechanisms to deliver the drug have evolved, the medication itself, remains the same as it was when it was first approved in 1971.

    “I don't understand at all why there is this marked increase in the drug,” said Dr. Georges Benjamin, executive director for the American Public Health Association. “Those innovations are interesting but not earth-shattering.”

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    corona-hospital_money2_i.png
    COVID-19 relief stabilized hospital finances in 2020, study finds
    corona-US-map-money_i.png
    States have yet to spend hundreds of millions of federal dollars to tackle COVID health disparities
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Nominate/Eligibility
      • 100 Most Influential People
      • 50 Most Influential Clinical Executives
      • Best Places to Work in Healthcare
      • Excellence in Governance
      • Health Care Hall of Fame
      • Healthcare Marketing Impact Awards
      • Top 25 Emerging Leaders
      • Top 25 Innovators
      • Diversity in Healthcare
        • - Luminaries
        • - Top 25 Diversity Leaders
        • - Leaders to Watch
      • Women in Healthcare
        • - Luminaries
        • - Top 25 Women Leaders
        • - Women to Watch
    • Events
      • Conferences
        • Transformation Summit
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Leadership Symposium
      • Galas
        • Health Care Hall of Fame Gala
        • Top 25 Women Leaders Gala
        • Best Places to Work Awards Gala
        • Top 25 Diversity Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Strategic Marketing
        • - Virtual Health
      • Webinars
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing